Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells.

@article{Hichami1995InvolvementOC,
  title={Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells.},
  author={Aziz Hichami and Elisabeth Boichot and No{\"e}lla Germain and Alain Bernard Legrand and I. Moodley and Vincent Lagente},
  journal={European journal of pharmacology},
  year={1995},
  volume={291 2},
  pages={
          91-7
        }
}
The effects of selective phosphodiesterase inhibitors, cyclic AMP (cAMP) elevating agents and stable analogues of cyclic nucleotides, on the release of arachidonate induced by N-formyl-Met-Leu-Phe (fMLP) were investigated on human peripheral blood mononuclear cells. The selective phosphodiesterase IV inhibitors, rolipram and Ro 20-1724, and the non-selective phosphodiesterase inhibitor, theophylline, elicited a concentration-dependent inhibition of arachidonate release (EC50 = 1.3 x 10(-6) M, 3… Expand
Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-α release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors
TLDR
The present data indicate that db-cAMP inhibits TNF-α release from human mononuclear cells through a PKA-dependent mechanism, in contrast, PDE 4 inhibitors elicit their in vitro anti-inflammatory activities via a PKG-dependent rather than Pka-dependent activation. Expand
Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.
TLDR
The results suggest that the inhibitory activity of PDE4 inhibitors on fMLP-induced production of superoxide anion production is mediated by db-cAMP rather than IL-10. Expand
Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function
TLDR
Data suggest that modulation of the PDE 4 isoform can regulate basophil responses whereas an association ofThe PDE 3/4 isoform with the regulation of HLMC function remains uncertain. Expand
Arachidonic Acid Regulates the Translocation of 5-Lipoxygenase to the Nuclear Membranes in Human Neutrophils*
TLDR
It is demonstrated that AA regulates the translocation of 5-LO in human PMN and unravels a novel mechanism of the cAMP-mediated inhibition of LT biosynthesis. Expand
Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9-Benzyladenine 1
Adenine derivatives substituted in position 9 have been demonstrated to have potent phosphodiesterase (PDE) inhibition properties with high selectivity toward PDE4. We compared the effects of variousExpand
Differential effect of phosphodiesterase inhibitors on IL‐13 release from peripheral blood mononuclear cells
TLDR
Results suggest that type 4 PDE inhibitors, alone or synergistically in combination with forskolin, inhibit PHA‐induced IL‐13 release from PBMC of atopic asthma patients by elevating intracellular cAMP concentrations. Expand
Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs.
TLDR
Data show that phosphodiesterase-4 isoenzyme may regulate the release of inflammatory mediators such as arachidonate from macrophages through an increase in intracellular cyclic adenosine monophosphate, and suggests that phosphorus-4 inhibitors have potential in the treatment of inflammatory disorders of the lung. Expand
Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
TLDR
Results demonstrate that the compounds derived from 9-benzyladenine, namely NCS 613, elicit anti-inflammatory activities and suggest that this compound may produce fewer gastrointestinal side effects than second-generation PDE4 inhibitors, such as RP 73401. Expand
Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.
TLDR
It is concluded that PDE inhibitors act via elevation of intracellular cAMP and in the model of LPS-induced BC, PDE IV inhibitors are more effective because (in contrast to PDE III inhibitors) they also attenuate TX release. Expand
Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma.
TLDR
The novel phosphodiesterase IV inhibitor CDP-840 selectively inhibited antigen-induced bronchoconstriction in conscious squirrel monkeys, and appears to be independent of any direct bronchodilator action. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
TLDR
The data suggest that cyclic AMP levels in human eosinophils are regulated by the action of a type IV PDE isoenzyme and that elevation of the intracellular cyclicAMP concentration by PDE IV inhibition can suppress the functional activity of these cells. Expand
The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea‐pig peritoneal macrophages
TLDR
The results indicate that guinea‐pig peritoneal macrophages contain a type IV cyclic AMP PDE which is predominantly membrane associated and a predominantly cytosolic calcium/calmodulin stimulated cyclic PDE, which contributes to cyclicAMP hydrolysis and regulation of superoxide generation in these cells. Expand
Inhibitory effect of prostaglandin E2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils.
TLDR
PGE2 appeared to inhibit not only initial events such as polyphosphoinositide breakdown but also turnover of inositol phospholipids, suggesting that a certain step from receptor activation to Ca2+ influx is mainly inhibited by PGE2. Expand
Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate.
TLDR
Theophylline inhibition of PMN function appeared to be associated with both an increase in cAMP and a decrease in intracellular calcium, which may be relevant to both the therapeutic and adverse pharmacologic actions of theophyllines. Expand
Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.
TLDR
The results suggest that Ro-20-1724-inhibited cAMP PDE plays a role in regulating eosinophil .O2- generation and the poor correlation between the PDE inhibitory actions of certain compounds and their effectiveness in elevating cAMP and inhibiting .O 2- suggests the existence of a barrier impeding access to the enzyme. Expand
Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing β‐adrenoceptor subtypes
TLDR
Compared on the guinea‐pig, bovine, and mouse trachea and porcine bronchus all precontracted with methacholine, Siquazodan was 100 fold more active than rolipram in pig tissues indicating the type III isoenzyme may be of greater functional significance in this tissue. Expand
The receptors for ATP and fMetLeuPhe are independently coupled to phospholipases C and A2 via G-protein(s). Relationship between phospholipase C and A2 activation and exocytosis in HL60 cells and human neutrophils.
TLDR
The relationship between phospholipase A2 and C activation and secretion was investigated in intact human neutrophils and differentiated HL60 cells and it was concluded that activation of phospholIPase C does not always lead to activation of phosphate A2. Expand
Beta2-Adrenergic Receptors on Eosinophils: Binding and Functional Studies
We have studied the binding characteristics and functional effects of β-adrenoceptors on human and guinea pig eosinophils. We determined the binding of the β-antagonist radioligand [125I]pindololExpand
Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.
TLDR
It is suggested that inhibitors of type IV phosphodiesterase have anti-inflammatory effects in the airways and may be useful in the treatment of asthma. Expand
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Theophylline has been a mainstay in the treatment of asthma for over 50 years. Its therapeutic value stems from a combination of antiinflammatory and bronchodilator activities in addition to itsExpand
...
1
2
3
...